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Abstract: Background and objective: as COVID-19 has triggered enormous human casualties and disastrous econom-
ic loss, the strategies to contain its spread are urgently needed. We aim to assess the value of our suspect case strategy 
on COVID-19 cases detection and ensure it to be a complement to the RT-PCR test. Materials and methods: from 
January 23 to April 30, 2020, patients admitted to our emergence isolation ward (EIW) were analyzed in this study. 
With RT-PCR as a reference standard, all participants were assigned to COVID-19 positive and negative groups. We 
compared the performance of the suspect case strategy, WBC, LYM, and chest radiography on COVID-19 detection. 
Results: one hundred twenty-five cases were analyzed in the study period. The receiver operating characteristic (ROC) 
curve revealed the sensitivity of WBC and LYM on COVID-19 detection was 92.11% and 76.31%, respectively. The 
sensitivity of the suspect case was 94.73%, and the sensitivity of chest CT was 53.33%. Statistically significant differ-
ences were observed for the suspect case, WBCs, LYM, and chest CT on COVID-19 detection. Discussion: suspect 
case strategy can help identify false negative RT-PCR tests and be a useful complement to RT-PCR in some countries 
with a tremendous shortage of RT-PCR agents and specialized laboratory during the COVID-19 outbreak. 
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1. Introduction 
In late December 2019, a novel pathogen, SARS 
CoV-2, first emerged in China and has evolved into a 
global pandemic
[1-2]
. COVID-19 is causing a worldwide 
medical healthy crisis and challenging the global 
healthcare system
[3]
. Although strict regulations and re-
strictions have been implemented to contain the virus’s 
spread, confirmed cases and death tolls caused by 
COVID-19 continue to rise throughout the world
[4]
. The-
se interventions undertook by some countries have a real 
effect on interrupting transmission and decreasing the 
confirmed cases; however, strategies against a potential 
rebound wave of transmission because of the gradual 
resumption of economic activities are still needed
[5-6]
. 
COVID-19 is found to have higher transmissibility
[7]
, 
and the majority of infected patients are asymptomatic or 
with mild symptoms
[8-9]
. Thus, early detection of positive 
cases is crucial. RT-PCR serves as the reference standard 
for COVID-19 diagnosis. However, RT-PCR has suffered 
from many flaws, such as the long turnaround times, the 
need for certified laboratories, expensive equipment, 
trained personnel, and high false-negative results
[10-11]
. 
The positive rate of RT-PCR for throat swab samples was 
reported to be about 30% to 60% at the initial presenta-
tion
[12]
. These flaws constrain RT-PCR as large-scale 
screening aiming at a rapid and reliable diagnosis of
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patients. An alternative strategy is needed to ensure that 
potential cases of COVID-19 are identified early and 
safely. 
Recent studies showed that some specific laboratory 
parameters were changed on COVID-19 patients
[13-15]
. 
These parameters might be quickly affected by a large 
variability, and those changes were also observed in 
healthy individuals. Characteristic radiographic findings 
have been reported on chest CTs of patients with 
COVID-19 infection. Chest CT is more sensitive than 
RT-PCR in the earliest (likely asymptomatic) phases of 
infection. However, normal chest CTs were also noted in 
patients with positive RT-PCR results but clinical symp-
toms. Those limitations also constrain laboratory param-
eters and chest CT as better COVID-19 detection tools. It 
is essential for a suspect case strategy helping to opti-
mize the existing medical resources
[17]
. However, its 
value on COVID-19 detection was uncertain, so we 
aimed to assess the performance of our suspect case 
strategy on COVID-19 detection. 
2. Materials and methods 
2.1 General setting 
Our hospital is located in the south of China and is 
far away from the COVID-19 outbreak zone. All patients 
registered in the emergence department with COVID-19 
exposure history or fever (T > 37.2°C) were managed in 
segregated areas of the ED (“fever clinic”), and com-
plete blood count (CBC) and chest radiographs with 
COVID-19 nucleic acid test were performed immediate-
ly at fever clinic. Subsequently, patients with COVID-19 
exposure history or undifferentiated fever (T > 37.2°C) 
were admitted into our emergence isolation ward (EIW) 
for investigations. COVID-19 positive cases detected in 
IW were transferred to a hospital designated for con-
firmed cases. Multiple COVID-19 samples would be 
performed until a positive sample was noted or reached 
the criteria for discharge when radiographic featured 
presenting with viral pneumonia. All images would be 
reviewed by two radiologists independently, and final 
decisions were reached by consensus. The minimum 
criteria for discharge were two negative COVID-19 
samples taken 24 hours apart with negative symptoms 
and chest radiographic.  
2.2 Suspect case criteria for COVID-19 
Exposure risk with any two items of clinical fea-
tures; all three items of clinical features.  
(1) Clinical features: (a) fever or respiratory symp-
toms; (b) imaging features of COVID-19 pneumonia; (c) 
WBCs < 9.93 ×10
9
 cells/L and LYM < 3.61×10
9
 cells/L.  
(2) COVID-19 exposure risk (in the last 14 
days before symptom onset): (a) a history of stay at the 
continuous transmission of local cases area; (b) contact-
ed fever or respiratory symptoms patients belong to the 
continuous transmission of local cases; (c) contacted 
with COVID-19 patients; (d) clustered onsets
[18]
. 
2.3 Study design and participants 
With RT-PCR as a reference standard, all partici-
pants were assigned to COVID-19 positive and negative 
groups. We analyzed initial plasma levels of WBCs, 
NEUT, LYM MON for COVID-19 prediction in each 
group. WBCs and LYM are potential diagnostic 
tests based on their AUC results. The performance of 
suspect case strategy, WBC, LYM, and chest radiography 
on detecting COVID-19 were assessed. We also com-
pared these selected tests as a potential diagnostic test on 
COVID-19 detection. 
2.4 Procedures protocol 
Blood samples and COVID-19 nasal swab samples 
were collected upon patients’ arrival, and experienced 
nurses performed the procedures wearing PPE and N95. 
All the samples were analyzed in our hospital’s labora-
tory, and the turnover period was 30 minutes for CBC 
and 6 hours for the COVID-19 nucleic test. Chest CT 
was performed in a cabin CT machine immediately af-
ter blood and nasal swab samples were collected. 
2.5 Data collection 
The medical records of patients were analyzed by 
the research team of our department, and epidemiologi-
cal history, blood results, and radiological data were ob-
tained in data collection forms from electronic medical 
records. A trained team of physicians reviewed the data. 
Information records included demographic data, medical 
history, exposure history, underlying comorbidities, 
symptoms, laboratory findings, and chest CT results.  
3. Results 
3.1 Basic characteristics and clinical labora-
 
74 | Zhongliang Ji et al. Advanced Emergency Medicine 
tory findings 
A total of 125 cases were analyzed in the study pe-
riod and 38 cases (38/125, 30%) were COVID-19 posi-
tive whereas 87 (87 /125, 70%) were negative. They 
were 59 males and 66 females. Their median age was 38 
(22–53) years. 108 (86%) of the patients had COVID-19 
exposure risk. 19 (15.2%) of the patients had underlying 
diseases, such as diabetes (2%), hypertension (8%), 
chronic obstructive pulmonary disease (2%), and cardi-
ovascular disease (2%). Clinical manifestations included 
fever (77/125, 62%), cough (67/125, 54%), sputum pro-
duction (44/125, 35%), short of breath (4/125, 3%), my-
algia or fatigue (12/125, 10%), headache (8/125, 6%), 
and diarrhea (12/125, 10%) (Table 1).
 








Age, years 38.0 (22.0-53.0) 42.0 (25.0-58.0) 36.0 (21.0-51.0) 0.57 
Sex    0.115 
Men 59 (47%) 37 (43%) 22 (58%)  
Women 66 (53%) 50 (57%) 16 (42%)  
Exposure risk 108 (86%) 34 (89%) 74 (85%) 0.512 
Comorbidity 
Diabetes 3 (2%) 1 (3%) 2 (2%) 0.912 
Hypertension 10 (8%) 4 (11%) 6 (7%) 0.495 
Chronic obstructive 
pulmonary disease 
3 (2%) 2 (5%) 1 (1%) 0.17 
Cardiovascular disease 3 (2%) 1 (3%) 2 (2%) 0.912 
Symptoms 
Fever 77 (62%) 24 (63%) 53 (61%) 0.815 
Cough 67 (54%) 17 (45%) 50 (57%) 0.192 
Sputum production 44 (35%) 9 (24%) 35 (40%) 0.076 
Short of breath 4 (3%) 2 (5%) 2 (2%) 0.390 
Myalgia or fatigue 12 (10%) 4 (11%) 8 (9%) 0.818 
Headache 8 (6%) 5 (13%) 3 (3%) 0.042* 
Diarrhea 12 (10%) 5 (13%) 7 (8%) 0.376 
Vomit 2 (1%) 0 (0%) 2 (2%) 0.350 
Table 1. Baseline characteristics and symptoms of the study patient 
* P < 0.05 was considered as statistically significant 
3.2 The performance of initial blood param-
eters and chest radiography on COVID-19 
patients 
Statistically significant differences were observed 
for WBC, NEUT, and LYM between COVID-19 positive 
and negative groups (Table 2). The receiver operating 
characteristic (ROC) curve revealed that the area under 
the curve (AUC) of WBC, NEUT, LYM, MON were 
0.719, 0.630, 0.696, 0.652, respectively (Table 3). WBCs 
and LYM were chosen as potential diagnostic tests in this 
study based on their higher AUC results. Youden’s index 
revealed cut-off values (WBC: 8.1150, LYM: 1.6750) 
(Figure. 1). Those cut-off values yielded a sensitivity of 
92.11% (95% confidence interval, CI = 77.5%-97.9%) 
and a specificity of 42.52% (95% confidence interval, CI 
= 32.1%-53.6%) for WBC, and sensitivity of 76.31% 
(95% confidence interval, CI = 59.4%-88.0%) and a 
specificity of 59.77% (95% confidence interval, CI = 
48.7%-70.0%) for LYM. The sensitivity of chest radio-
graphic scan was 53.33% (95% confidence interval, CI = 
38.0%-68.0%), and the specificity was 82.5% (95% con-
fidence interval, CI = 72.0%-89.8%) (Table 4). 
3.3 The performance of suspect case strategy 
on COVID-19 patients   
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Sixty (60/125, 48%) patients fulfilled suspect case 
criteria. 36 (36/60, 60%) were COVID-19 positive 
whereas 24 (24 /60, 40%) were negative. The sensitivity 
of suspect case was 94.73% (95% confidence interval, CI 
= 80.9%-99.1%), and the specificity was 72.41% (95% 
confidence interval, CI = 61.6%-81.2%) (Table 4). Sta-
tistically significant differences were observed for sus-
pect cases, WBCs, LYM, and chest radiography on 
COVID-19 detection (Table 5).
 
Parameters Unit COVID-19 positive COVID-19 negative P value 
WBC ×109 cells/L 5.67±1.70 7.74±3.09 0.000 
Neutrophils ×109 cells/L 3.73±1.46 4.98±2.88 0.013 
Lymphocytes ×109 cells/L 1.45±1.46 2.04±1.10 0.003 
Monocytes ×109 cells/L 0.43±0.18 0.76±1.71 0.230 
Table 2. Averaged blood parameters of patients 
* P<0.05 was considered as statistically significant 
 
Variable AUC SE P-value 95%CI Youden Index Cut-off values 
WBC 0.719 0.047 0.000* 0.628 to 0.811 0.358  7.7000  
LYM 0.696 0.050 0.001* 0.598 to 0.793 0.346 1.6500 
NEUT 0.630 0.051 0.021* 0.530 to 0.731 0.239 4.3000 
MON 0.652 0.53 0.007* 0.547 to 0.765 0.236 0.4950 
Table 3. Discriminative performance of prediction for COVID-19 
* P < 0.05 was considered as statistically significant 
 
Test Results(n) Test performance (%) 
TP   
FP  




PPV (95%CI) NPV (95%CI) 
Suspect case  36 63 24 2 94.73(80.9-99.1) 72.41 (61.6-81.2) 60.00(46.5-72.2) 96.92 (88.4-99.5) 
WBC 35 50 37 3 92.11(77.5-97.9) 42.52 (32.1-53.6) 41.18(30.8-52.4) 92.50(78.5-98.0) 
LYM 29 35 52 9 76.31(59.4-88.0) 59.77(48.7-70.0) 45.31(33.0-58.2) 85.24(73.3-92.6) 
CT 24 14 66 21 53.33(38.0-68.0) 82.5 (72.0-89.8) 63.16 (46.0-77.7) 75.86 (65.3-84.1) 
Table 4. Prediction performance of COVID-19 with different screening test 
CT = chest CT  TP = true positive, TN = true negative, FP = false positive, FN = false negative, PPV = positive predictive value, 























24 50 35 14 
Table 5. Selected screening test on COVID-19 detection analysis
CT = chest CT, * P < 0.05 was considered as statistical significant 
 
4. Discussion 
Early diagnosis and isolate patients with COVID-19 
exposure history or respiratory symptoms are crucial to 
containing the pandemic. The COVID-19 exposure risk 
and clinical features are associated with a positive 
SARS-CoV-2 test
[19]
. In our study, 34 (89%) COVID-19 
patients had positive exposure history. However, there 
was no difference in exposure history between the two 
groups. The most common symptoms at the onset of ill-
ness were fever (24 [63%]), cough (17 [45%]), sputum 
production (9 [24%]). Less common symptoms were 
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headache, diarrhea, and vomiting (Table 1). However, 
there was also no difference in significant clinical find-
ings between the two groups except the headache. The 
reason for the headache discrepancy is likely to be the 
low number of patients enrolled in our study. So it is 
difficult to differentiate and screen patients just with ex-
posure history and clinical symptoms in the emergency 
department setting. 
Certain blood biochemical indexes were associated 
with COVID-19 patients
[20-21]
. The most common labor-
atory abnormalities observed in this study were de-
pressed total WBCs, LYM, NEUT (Table 2). They are 
consistent with the current study
[22]
, and WBCs and LYM 
achieved excellent diagnosis performance with AUC = 
0.719 and 0.630 (Table 3). With RT-PCR results as a 
reference, our suspect case had a better sensitivity and 
specificity on COVID-19 detection compared with 
WBCs and LYM. Better performance also was found in 
positive predictive value and negative predictive value, 
respectively. These biochemical indexes need to incor-
porate other diagnostic factors to achieve excellent per-
formance on COVID-19 detection. 
Chest CT was reported to be a valuable diagnostic 
tool for COVID-19
[23]
. Characteristic CT features of 
COVID-19 patients were described in the recently pub-
lished literature
[24-26]
. In our study, about 63% (24/38) 
cases had typical initial CT features consistent with 
COVID-19 positive RT-PCR. The sensitivity and speci-
ficity of chest CT scan on COVID-19 detection were 
53.33% (95% CI = 38.0%-68.0%) and 82.5% (95% CI 
= 72.0%-89.8%). One study’s results described by Ai T, 
etc.al, were better than ours
[27]
. The discrepancy between 
the two results is likely to be different from enrolled pa-
tients and settings. Ai's study was observed in Wuhan 
with a higher COVID-19 prevalence than our city cause; 
this study enrolled in patients who came from the emer-
gence department. CT can decrease the chance of 
false-negative results in the RT-PCR assay. Many poten-
tial COVID-19 patients with first or second negative 
RT-PCR tests were found and reported with positive CT 
findings in our clinical practice
[28-31]
. Therefore, multiple 
swab samples were collected for COVID-19 detection 
until positive samples were noted or met the criteria for 
discharge. Positive chest CT had a good performance on 
COVID-19 detection.  
Given one COVID-19 case’s inappropriate man-
agement in the emergence department can result in large 
numbers of individuals exposure and potential infec-
tion
[32]
. Isolating all patients with respiratory symptoms 
or screening all patients by one diagnostic tool may not 
detect all COVID-19 patients. The suspected case strat-
egy incorporated epidemiology risk and clinical features 
combining with WBCS, LYM, and chest CT, it can 
compensate for the above shortcoming, and its value on 
COVD-19 detection is better than any single diagnostic 
tool (Table 5). The suspect case also can be a potential 
diagnostic tool for COVID-19. 
5. Limitation 
Because enrolled cases were limited in the isolation 
room, we cannot extend the detection value of the sus-
pect case strategy to all the potential COVID-19 patients 
in the emergence room. Future studies should include all 
potential cases in the ER, and multicenter studies will 
optimize the practical applicability of the suspect case 
strategy. 
6. Conclusion 
A suspect case strategy can help to ensure appropri-
ate triage and optimize testing resources, but it also 
can be a potential diagnostic tool for COVID-19 detec-
tion. Combining appropriate specific hematological pa-
rameters with chest radiography can be helpful to identi-
fy false positive/negative RT-PCR tests. Blood test anal-
ysis and chest radiography might be used as an alterna-
tive to RT-PCR for identifying COVID-19 positive pa-
tients in those countries which suffer from a massive 
shortage of RT-PCR reagents and specialized laboratory. 
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